Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

BACKGROUND: Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%–45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. Th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Morin, Andrew, Soane, Caroline, Pierce, Angela, Sanford, Bridget, Jones, Kenneth L, Crespo, Michele, Zahedi, Shadi, Vibhakar, Rajeev, Mulcahy Levy, Jean M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236404/
https://ncbi.nlm.nih.gov/pubmed/32642704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa051
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados